Oncobiologics: Cantor Fitzgerald Healthcare Conference (Oncobiologics) - Jul 30, 2016 - "Safety: Adverse events balanced across all three arms of the study"; "Immunogenicity: One subject had ADA detected in EU-Avastin arm at Day 98 (Last visit), No other ADAs detected, No neutralizing antibodies detected in any arm of the study"
P1 data • Biosimilar
|